| 2026-08-13 | 10-Q | 10.5 | Form of Performance Stock Unit Agreement under the Pelthos Therapeutics Inc. 2023 Equity Incentive Plan |
|---|
| 2026-05-21 | 8-K | 10.1 | Separation and Release Agreement between Pelthos Therapeutics Inc. and Francis Knuettel II, dated May 15, 2026. |
|---|
| 2026-05-14 | 10-Q | 10.6 | First Amendment to Executive Employment Agreement between Pelthos Therapeutics Inc. and Sai Rangarao, dated April 6, 2026 |
|---|
| 2026-05-14 | 10-Q | 10.5 | First Amendment to Executive Employment Agreement between Pelthos Therapeutics Inc. and Scott Plesha, dated April 9, 2026 |
|---|
| 2026-04-10 | 8-K | 10.1 | Employment Agreement between Pelthos Therapeutics Inc. and John M. Gay dated April 10, 2026 |
|---|
| 2026-01-13 | 8-K | 10.1 | Venture Loan and Security Agreement, dated as of January 12, 2026, by and among Pelthos Therapeutics Inc., LNHC, Inc., Channel Therapeutics Corporation and Horizon Technology Finance Corporation. |
|---|
| 2026-01-02 | 8-K | 10.2 | Down Payment Agreement for Xeglyze Assets Purchase, dated as of November 20, 2025, by and between Hatchtech Pty Ltd, as Seller and Pelthos Therapeutics Inc. as Buyer. |
|---|
| 2026-01-02 | 8-K | 10.1 | Asset Purchase Agreement, dated as of December 23, 2025, by and between Pelthos Therapeutics Inc., as Purchaser, and Hatchtech Pty Ltd ACN 098 559 409, as Seller. |
|---|
| 2025-11-07 | 8-K | 10.8 | License and API Supply Agreement, effective as of November 6, 2025, by and among Pelthos Therapeutics Inc., Ferrer Internacional, S.A. and Interquim, S.A.U. |
|---|
| 2025-11-07 | 8-K | 10.7 | Asset Purchase Agreement, dated as of November 6, 2025, by and between Pelthos Therapeutics Inc., as Purchaser, and Biofrontera Inc., as Seller. |
|---|
| 2025-11-07 | 8-K | 10.6 | Amendment No. 1 to Assignment Agreement, dated as of November 6, 2025, by and between Ligand Pharmaceuticals Incorporated, as Assignee, and LNHC, Inc., as Assignor. |
|---|
| 2025-11-07 | 8-K | 10.5 | Amendment No. 1 to Purchase and Sale Agreement, dated as of November 6, 2025, by and among Channel Pharmaceutical Corporation and Pelthos Therapeutics Inc., as the Seller Parties, and Nomis RoyaltyVest LLC, Ligand Pharmaceuticals Incorporated and Madison Royalty LLC, as Purchasers. |
|---|
| 2025-11-07 | 8-K | 10.4 | Forn of Amended and Restated Lock-Up Agreement (Ligand and other investors). |
|---|
| 2025-11-07 | 8-K | 10.3 | Registration Rights Agreement, dated as of November 6, 2025, by and among Pelthos Therapeutics Inc. and each of the buyers thereto. |
|---|
| 2025-11-07 | 8-K | 10.2 | Pledge Agreement, dated as of November 6, 2025, by and among Pelthos Therapeutics Inc., as Pledgor, and Ligand Pharmaceuticals Incorporated, as Secured Party, in its capacity as Collateral Agent. |
|---|
| 2025-11-07 | 8-K | 10.1 | Securities Purchase Agreement, dated as of November 6, 2025, by and among Pelthos Therapeutics Inc. and each of the investors thereto. |
|---|
| 2025-09-16 | 8-K/A | 10.24 | Exclusive License and Sublicense Agreement dated March 24, 2025, by and between Ligand Pharmaceuticals Incorporated and LNHC, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.23 | Master Services Agreement for Product Supply dated as of March 24, 2025, by and between Ligand Pharmaceuticals Incorporated and LNHC, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.22 | Assignment Agreement dated March 24, 2025, by and between Ligand Pharmaceuticals Incorporated and LNHC, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.21 | Contract Manufacturing Agreement dated February 12, 2025 by and between LNHC, Inc. and Orion Corporation. |
|---|
| 2025-09-16 | 8-K/A | 10.20 | Third Amendment to Lease dated October 17, 2023 by and between TBC Stirrup Creek Owner LLC and LNHC, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.19 | Second Amendment to Lease dated November 23, 2021 by and between Copper II 202, LLC and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.18 | Lease dated January 18, 2021 by and between Copper II 2020, LLC and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.17 | Seventh Amendment to Amended, Restated and Consolidated License Agreement dated March 12, 2025, by and between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.16 | Sixth Amendment to Amended, Restated and Consolidated License Agreement dated July 26, 2024, by and between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.15 | Fifth Amendment to Amended, Restated and Consolidated License Agreement dated October 27, 2021, by and between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.14 | Fourth Amendment to Amended, Restated and Consolidated License Agreement dated November 26, 2018, by and between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.13 | Third Amendment to Amended, Restated and Consolidated License Agreement dated November 1, 2018, by and between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.12 | Second Amendment to Amended, Restated and Consolidated License Agreement dated April 12, 2016, by and between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.11 | First Amendment to Amended, Restated and Consolidated License Agreement dated as of November 20, 2012, between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.10 | Amended, Restated and Consolidated License Agreement dated June 27, 2012, by and between The University of North Carolina at Chapel Hill and Novan, Inc. |
|---|
| 2025-09-16 | 8-K/A | 10.9 | Amendment, Assignment and Assumption Agreement dated September 11, 2023, by and between Novan, Inc., LNHC, Inc. and Reedy Creek Investments LLC. |
|---|
| 2025-09-16 | 8-K/A | 10.8 | Royalty and Milestone Payments Purchase Agreement dated April 29, 2019, by and between Novan, Inc. and Reedy Creek Investments LLC. |
|---|
| 2025-09-16 | 8-K/A | 10.7 | Second Amendment to License Agreement dated October 5, 2018, by and between Novan, Inc. and Sato Pharmaceutical Co., Ltd. |
|---|
| 2025-09-16 | 8-K/A | 10.6 | First Amendment to License Agreement dated January 12, 2017, by and between Novan, Inc. and Sato Pharmaceutical Co., Ltd. |
|---|
| 2025-09-16 | 8-K/A | 10.5 | License Agreement dated January 12, 2017, by and between Novan, Inc. and Sato Pharmaceutical Co., Ltd. |
|---|
| 2025-07-02 | 8-K | 10.21 | Transition Services Agreement, dated July 1, 2025, by and between Ligand Pharmaceuticals Incorporated and LNHC, Inc. |
|---|
| 2025-07-02 | 8-K | 10.20 | Employee Lease Agreement, dated July 1, 2025, by and between Ligand Pharmaceuticals Incorporated and Pelthos Therapeutics Inc. |
|---|
| 2025-07-02 | 8-K | 10.19 | Executive Employment Agreement, dated July 1, 2025, between Pelthos Therapeutics Inc. and Sai Rangarao. |
|---|
| 2025-07-02 | 8-K | 10.18 | Executive Employment Agreement, dated July 1, 2025, between Pelthos Therapeutics Inc. and Francis Knuettel II. |
|---|
| 2025-07-02 | 8-K | 10.17 | Executive Employment Agreement, dated July 1, 2025, between Pelthos Therapeutics Inc. and Scott Plesha. |
|---|
| 2025-07-02 | 8-K | 10.16 | Form of Restricted Stock Unit Agreement under the Pelthos Therapeutics Inc. Amended and Restated 2023 Equity Incentive Plan. |
|---|
| 2025-07-02 | 8-K | 10.15 | Form of Stock Option Agreement under the Pelthos Therapeutics Inc. Amended and Restated 2023 Equity Incentive Plan. |
|---|
| 2025-07-02 | 8-K | 10.14 | Pelthos Therapeutics Inc. Amended and Restated 2023 Equity Incentive Plan. |
|---|
| 2025-07-02 | 8-K | 10.13 | Purchase and Sale Agreement, dated as of July 1, 2025, by and among Channel Therapeutics Corporation and Channel Pharmaceutical Corporation, as the Seller Parties and Nomis RoyaltyVest LLC, Ligand Pharmaceuticals Incorporated and Madison Royalty LLC, as the Purchasers. |
|---|
| 2025-07-02 | 8-K | 10.12 | Purchase and Sale Agreement, dated as of July 1, 2025, by and among Channel Therapeutics Corporation and LNHC, Inc., as the Seller Parties and Nomis RoyaltyVest LLC, as the Purchaser. |
|---|
| 2025-07-02 | 8-K | 10.11 | Intellectual Property Assignment and Assumption Agreement, dated as of July 1, 2025, by and between Channel Therapeutics Corporation and Channel Pharmaceutical Corporation. |
|---|
| 2025-07-02 | 8-K | 10.10 | Contribution Agreement, dated as of July 1, 2025, by and between Channel Therapeutics Corporation and Channel Pharmaceutical Corporation. |
|---|
| 2025-07-02 | 8-K | 10.9 | Form of Indemnification Agreement. |
|---|
| 2025-07-02 | 8-K | 10.8 | Registration Rights Agreement. |
|---|
| 2025-07-02 | 8-K | 10.7 | Form of Series A Convertible Preferred Stockholder Letter. |
|---|
| 2025-07-02 | 8-K | 10.6 | Amendment No. 1 to Securities Purchase Agreement, dated as of July 1, 2025, by and among Channel Therapeutics Corporation, LNHC Inc., and each of the investors thereto. |
|---|
| 2025-05-13 | 10-Q | 10.11 | First Amendment to Promissory Note dated May 12, 2025. |
|---|
| 2025-05-13 | 10-Q | 10.10 | Promissory Note dated May 8, 2025. |
|---|
| 2025-04-17 | 8-K | 10.6 | Form of Registration Rights Agreement. |
|---|
| 2025-04-17 | 8-K | 10.5 | Form of Lock-Up Agreement (Nomis Bay, Ligand and other investors) |
|---|
| 2025-04-17 | 8-K | 10.4 | Form of Lock-Up Agreement (certain investment company) |
|---|
| 2025-04-17 | 8-K | 10.3 | Form of Lock-Up Agreement (certain investors who have entered the Securities Purchase Agreement) |
|---|
| 2025-04-17 | 8-K | 10.2 | Form of Lock-Up Agreement (Channel’s executive officers and directors) |
|---|
| 2025-04-17 | 8-K | 10.1 | Securities Purchase Agreement, dated as of April 16, 2025, by and among Channel Therapeutics Corporation, LNHC Inc., and each of the investors thereto. |
|---|
| 2025-03-03 | 8-K | 10.1 | Promissory Note dated February 25, 2025 |
|---|
| 2024-11-18 | 8-K | 10.1 | Form of Indemnification Agreement |
|---|
| 2024-11-13 | 10-Q | 10.1 | Second Amendment to the Chromocell Therapeutics Corporation 2023 Equity Incentive Plan. |
|---|
| 2024-07-29 | 8-K | 10.3 | Registration Rights Agreement by and between the Company and Tikkun, dated July 26, 2024. |
|---|
| 2024-07-29 | 8-K | 10.2 | Common Stock Purchase Agreement by and the Company and Tikkun, dated July 26, 2024. |
|---|
| 2024-07-29 | 8-K | 10.1 | Securities Purchase Agreement by and between the Company and the Holder, dated July 24, 2024. |
|---|
| 2024-05-15 | 10-Q | 10.3 | Employment Agreement (Francis Knuettel II) (filed herewith). |
|---|
| 2024-05-15 | 10-Q | 10.2 | Promissory Note Issued by the Company (Camden Capital) (filed herewith). |
|---|
| 2024-05-15 | 10-Q | 10.1 | Side Letter to Amended and Restated Consultant Agreement (Camden Capital) (filed herewith). |
|---|